Baxter(US:BAX) Prnewswireยท2025-10-20 01:03Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP suffered systemic defects leading to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths associated with these defects but failed to adequately address the issues through customer alerts [3]. - The company's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Impact on Stock and Legal Proceedings - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the company's stock price dropped by 22.4%, closing at $21.76 [4]. - Investors who suffered losses between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi, LLP to discuss their legal options, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].